Literature DB >> 20161310

Decreasing procedural pain over time of left prefrontal rTMS for depression: initial results from the open-label phase of a multi-site trial (OPT-TMS).

Berry S Anderson1, Katie Kavanagh, Jeffrey J Borckardt, Ziad H Nahas, Samet Kose, Sarah H Lisanby, William M McDonald, David Avery, Harold A Sackeim, Mark S George.   

Abstract

BACKGROUND: There is much interest in whether daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) over several weeks may become a clinically useful antidepressant treatment. Although rTMS appears largely safe, many patients report that this procedure is somewhat painful, which may restrict its ultimate appeal and utility. We analyzed interim results from the open-label phase of a multi-site randomized trial of rTMS as a treatment for depression to investigate whether the procedural pain of left prefrontal rTMS changes over time.
METHODS: Patients with unipolar depression who had failed to respond during at least three weeks of the sham-controlled double-masked rTMS were then offered three more weeks (15 sessions) of open-label rTMS. Retrospective pain ratings and state emotional factors from 20 subjects were assessed using visual analog scales (VAS) recorded on computers before and after each treatment (289 sessions).
RESULTS: Over the 15 treatment sessions, subjective reports of the painfulness of rTMS decreased 48% from baseline. This reduction, although greatest in the first few days, continued steadily (average 2.11 points per session) over the 3 weeks of treatment. The analysis found a significant effect for rTMS-session (p<0.0001) on rTMS-procedural pain over and above changes in subjective emotional states.
CONCLUSION: The procedural pain of left, prefrontal rTMS decreases over time, apparently independently of other emotional changes. Since rTMS scalp pain may decline over time, physicians and patients may decide to continue treatment despite initial discomfort. These observational data can be better tested once the data from the blinded phase of the trial becomes available.

Entities:  

Mesh:

Year:  2009        PMID: 20161310      PMCID: PMC2699309          DOI: 10.1016/j.brs.2008.09.001

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  8 in total

1.  Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation.

Authors:  U Herwig; F Padberg; J Unger; M Spitzer; C Schönfeldt-Lecuona
Journal:  Biol Psychiatry       Date:  2001-07-01       Impact factor: 13.382

2.  Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled study.

Authors:  David H Avery; Paul E Holtzheimer; Walid Fawaz; Joan Russo; John Neumaier; David L Dunner; David R Haynor; Keith H Claypoole; Chandra Wajdik; Peter Roy-Byrne
Journal:  J Nerv Ment Dis       Date:  2007-05       Impact factor: 2.254

3.  Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex.

Authors:  M S George; E M Wassermann; W A Williams; J Steppel; A Pascual-Leone; P Basser; M Hallett; R M Post
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

4.  Imaging human intra-cerebral connectivity by PET during TMS.

Authors:  P Fox; R Ingham; M S George; H Mayberg; J Ingham; J Roby; C Martin; P Jerabek
Journal:  Neuroreport       Date:  1997-08-18       Impact factor: 1.837

5.  Postoperative left prefrontal repetitive transcranial magnetic stimulation reduces patient-controlled analgesia use.

Authors:  Jeffrey J Borckardt; Mitchel Weinstein; Scott T Reeves; F Andrew Kozel; Ziad Nahas; Arthur R Smith; T Karl Byrne; Katherine Morgan; Mark S George
Journal:  Anesthesiology       Date:  2006-09       Impact factor: 7.892

6.  Reducing pain and unpleasantness during repetitive transcranial magnetic stimulation.

Authors:  Jeffrey J Borckardt; Arthur R Smith; Kelby Hutcheson; Kevin Johnson; Ziad Nahas; Berry Anderson; M Bret Schneider; Scott T Reeves; Mark S George
Journal:  J ECT       Date:  2006-12       Impact factor: 3.635

7.  Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.

Authors:  John P O'Reardon; H Brent Solvason; Philip G Janicak; Shirlene Sampson; Keith E Isenberg; Ziad Nahas; William M McDonald; David Avery; Paul B Fitzgerald; Colleen Loo; Mark A Demitrack; Mark S George; Harold A Sackeim
Journal:  Biol Psychiatry       Date:  2007-06-14       Impact factor: 13.382

8.  Nimodipine increases CSF somatostatin in affectively ill patients.

Authors:  P J Pazzaglia; M S George; R M Post; D R Rubinow; C L Davis
Journal:  Neuropsychopharmacology       Date:  1995-08       Impact factor: 7.853

  8 in total
  11 in total

1.  Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trial.

Authors:  Kevin A Johnson; Mirza Baig; Dave Ramsey; Sarah H Lisanby; David Avery; William M McDonald; Xingbao Li; Elisabeth R Bernhardt; David R Haynor; Paul E Holtzheimer; Harold A Sackeim; Mark S George; Ziad Nahas
Journal:  Brain Stimul       Date:  2012-03-14       Impact factor: 8.955

Review 2.  Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research.

Authors:  Simone Rossi; Mark Hallett; Paolo M Rossini; Alvaro Pascual-Leone
Journal:  Clin Neurophysiol       Date:  2009-10-14       Impact factor: 3.708

3.  Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving.

Authors:  Xingbao Li; Karen J Hartwell; Max Owens; Todd Lematty; Jeffrey J Borckardt; Colleen A Hanlon; Kathleen T Brady; Mark S George
Journal:  Biol Psychiatry       Date:  2013-02-26       Impact factor: 13.382

Review 4.  The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.

Authors:  Tarique Perera; Mark S George; Geoffrey Grammer; Philip G Janicak; Alvaro Pascual-Leone; Theodore S Wirecki
Journal:  Brain Stimul       Date:  2016-03-16       Impact factor: 8.955

5.  The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial.

Authors:  Jeffrey J Borckardt; Ziad H Nahas; John Teal; Sarah H Lisanby; William M McDonald; David Avery; Valerie Durkalski; Martina Pavlicova; James M Long; Harold A Sackeim; Mark S George
Journal:  Brain Stimul       Date:  2013-05-21       Impact factor: 8.955

6.  Magnetic Resonance Imaging-Guided, Open-Label, High-Frequency Repetitive Transcranial Magnetic Stimulation for Adolescents with Major Depressive Disorder.

Authors:  Christopher A Wall; Paul E Croarkin; Mandie J Maroney-Smith; Laura M Haugen; Joshua M Baruth; Mark A Frye; Shirlene M Sampson; John D Port
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-05       Impact factor: 2.576

7.  Meta-Review of Metanalytic Studies with Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depression.

Authors:  Bernardo Dell'osso; Giulia Camuri; Filippo Castellano; Vittoria Vecchi; Matteo Benedetti; Sara Bortolussi; A Carlo Altamura
Journal:  Clin Pract Epidemiol Ment Health       Date:  2011-10-26

8.  Personalized TMS: role of RNA genotyping.

Authors:  Shawna Chan; Robert Bota
Journal:  Ment Illn       Date:  2019-11-04

9.  A randomized trial to examine the mechanisms of cognitive, behavioral and mindfulness-based psychosocial treatments for chronic pain: Study protocol.

Authors:  M A Day; D M Ehde; J Burns; L C Ward; J L Friedly; B E Thorn; M A Ciol; E Mendoza; J F Chan; S Battalio; J Borckardt; M P Jensen
Journal:  Contemp Clin Trials       Date:  2020-04-14       Impact factor: 2.226

Review 10.  Repetitive transcranial magnetic stimulation as a potential treatment approach for cannabis use disorder.

Authors:  Tonisha Kearney-Ramos; Margaret Haney
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-03-04       Impact factor: 5.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.